Paper Details

  1. Home
  2. Paper Details

Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

Author: BellosNicholas, ClotetBonaventura, HillAndrew M, JohnsonMargaret, SmetsErik, StollMatthias

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Darunavir/ritonavir (DRV/r) was a cost-effective treatment option for highly treatment-experienced patients with HIV-1 infection. Compared to control protease inhibitor (PI)-based HAART, DRV/r was associated with a 73-78% lower cost of achieving undetectable plasma HIV-RNA levels.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Very few studies have evaluated the cost of highly active antiretroviral therapy (HAART) per successful treatment in HIV-infected patients. OBJECTIVES: To evaluate the cost of achieving undetectable plasma HIV-RNA levels in highly treatment-experienced, HIV-1-infected adults receiving d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/11587460-000000000-00000

データ提供：米国国立医学図書館（NLM）

Darunavir: A Cost-Effective Option for HIV Treatment

In the fight against HIV/AIDS, researchers are constantly searching for effective and affordable treatments. This study investigates the cost-effectiveness of darunavir/ritonavir (DRV/r) in achieving undetectable HIV RNA levels in highly treatment-experienced patients. The authors compared DRV/r to other protease inhibitor-based highly active antiretroviral therapy (HAART) regimens, looking at both the cost of treatment and the likelihood of achieving viral suppression.

The Price of Success in HIV Treatment

The study found that while the absolute cost of DRV/r was slightly higher than control PI-based HAART, the annual cost per patient of achieving undetectable plasma HIV-RNA levels was significantly lower with DRV/r. This suggests that DRV/r is a more cost-effective treatment option for this patient population, making it a valuable tool for managing HIV infection and improving patient outcomes. It's like finding a shortcut through the desert - while it might involve a slightly different path, it leads to the same destination more efficiently.

Ensuring Access to Effective Treatment

This study highlights the importance of considering cost-effectiveness when choosing treatment options for HIV infection. It emphasizes the need for healthcare systems to prioritize access to affordable and effective medications for all patients. Remember, the desert can be unforgiving, but with the right resources and support, we can find our way to a healthier future.

Dr. Camel's Conclusion

This study offers valuable insights into the economic aspects of HIV treatment. It demonstrates that DRV/r is a cost-effective option for achieving viral suppression in highly treatment-experienced patients. It underscores the need for healthcare systems to prioritize access to affordable and effective medications for all patients, ensuring a more equitable approach to HIV care. Think of it as providing a lifeline in the desert - it's crucial to ensure that everyone has access to the resources they need to thrive.

Date :
  1. Date Completed 2011-04-21
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21182345

DOI: Digital Object Identifier

10.2165/11587460-000000000-00000

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.